AstraZeneca's COVID vaccine suffers a setback in nasal spray trial

AstraZeneca's COVID vaccine suffers a setback in nasal spray trial Antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement. https://ift.tt/iHuKFeT